- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Severe Gastritis after Administration of Nivolumab and Ipilimumab ; volume:11 ; number:2 ; year:2018 ; pages:549-556
Case reports in oncology ; 11, Heft 2 (2018), 549-556
- Creator
-
Nishimura, Yoshito
Yasuda, Miho
Ocho, Kazuki
Iwamuro, Masaya
Yamasaki, Osamu
Tanaka, Takehiro
Otsuka, Fumio
- DOI
-
10.1159/000491862
- URN
-
urn:nbn:de:101:1-2018122623194945170174
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nishimura, Yoshito
- Yasuda, Miho
- Ocho, Kazuki
- Iwamuro, Masaya
- Yamasaki, Osamu
- Tanaka, Takehiro
- Otsuka, Fumio
Other Objects (12)
Retinal toxicity after initial administration of nivolumab and ipilimumab
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
Retinal toxicity after initial administration of nivolumab and ipilimumab
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
Retinal toxicity after initial administration of nivolumab and ipilimumab
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma